Literature DB >> 19721850

Autosomal dominant polycystic kidney disease: 2009 update for internists.

William M Bennett1.   

Abstract

Because autosomal dominant polycystic kidney disease (ADPKD) is one of the most common genetic abnormalities seen in today's medical practice, many internists will likely treat patients affected by this condition. Genetic abnormalities have been increasingly recognized, and the pathophysiology of the disease is beginning to be unraveled. Because of advances in imaging technology, surrogate markers for disease progression have allowed clinical studies of newer therapeutic agents to proceed. In the near future, therapies for this common genetic disease may be available to either prevent or stabilize the disease course for many affected individuals.

Entities:  

Keywords:  Genetic; Hypertension; Kidney; Polycystic kidney diseases; Tubule

Mesh:

Year:  2009        PMID: 19721850      PMCID: PMC2732773          DOI: 10.3904/kjim.2009.24.3.165

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  19 in total

Review 1.  Polycystic kidney disease.

Authors:  Patricia D Wilson
Journal:  N Engl J Med       Date:  2004-01-08       Impact factor: 91.245

Review 2.  Autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris; Yves Pirson
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

3.  Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease.

Authors:  Peter C Harris; Kyongtae T Bae; Sandro Rossetti; Vicente E Torres; Jared J Grantham; Arlene B Chapman; Lisa M Guay-Woodford; Bernard F King; Louis H Wetzel; Deborah A Baumgarten; Philip J Kenney; Mark Consugar; Saulo Klahr; William M Bennett; Catherine M Meyers; Qin Jean Zhang; Paul A Thompson; Fang Zhu; J Philip Miller
Journal:  J Am Soc Nephrol       Date:  2006-10-11       Impact factor: 10.121

4.  Volume progression in polycystic kidney disease.

Authors:  Jared J Grantham; Vicente E Torres; Arlene B Chapman; Lisa M Guay-Woodford; Kyongtae T Bae; Bernard F King; Louis H Wetzel; Deborah A Baumgarten; Phillip J Kenney; Peter C Harris; Saulo Klahr; William M Bennett; Gladys N Hirschman; Catherine M Meyers; Xiaoling Zhang; Fang Zhu; John P Miller
Journal:  N Engl J Med       Date:  2006-05-18       Impact factor: 91.245

5.  Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2.

Authors:  R Torra; C Badenas; A Darnell; C Nicolau; V Volpini; L Revert; X Estivill
Journal:  J Am Soc Nephrol       Date:  1996-10       Impact factor: 10.121

6.  A "two-hit" model of cystogenesis in autosomal dominant polycystic kidney disease?

Authors:  Y Pei
Journal:  Trends Mol Med       Date:  2001-04       Impact factor: 11.951

7.  Ciprofloxacin activity in cyst fluid from polycystic kidneys.

Authors:  L W Elzinga; T A Golper; A L Rashad; M E Carr; W M Bennett
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

Review 8.  Advances in the pathogenesis and treatment of polycystic kidney disease.

Authors:  Vishal Patel; Renuka Chowdhury; Peter Igarashi
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-03       Impact factor: 2.894

9.  Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease.

Authors:  Sandro Rossetti; Mark B Consugar; Arlene B Chapman; Vicente E Torres; Lisa M Guay-Woodford; Jared J Grantham; William M Bennett; Catherine M Meyers; Denise L Walker; Kyongtae Bae; Qin Jean Zhang; Paul A Thompson; J Philip Miller; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2007-06-20       Impact factor: 10.121

10.  Trimethoprim-sulfamethoxazole in cyst fluid from autosomal dominant polycystic kidneys.

Authors:  L W Elzinga; T A Golper; A L Rashad; M E Carr; W M Bennett
Journal:  Kidney Int       Date:  1987-12       Impact factor: 10.612

View more
  5 in total

1.  Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease.

Authors:  Imed Helal; Berenice Reed; Kim McFann; Xiang-Dong Yan; Godela M Fick-Brosnahan; Melissa Cadnapaphornchai; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-08       Impact factor: 8.237

2.  A comparison of the effects of losartan and ramipril on blood pressure, renal volume and progression in polycystic kidney disease: A 5-Year follow-up.

Authors:  S Ulusoy; G Ozkan; P Kosucu; K Kaynar; I Eyuboglu
Journal:  Hippokratia       Date:  2012-04       Impact factor: 0.471

3.  ADPKD: Prototype of Cardiorenal Syndrome Type 4.

Authors:  Grazia Maria Virzì; Valentina Corradi; Anthi Panagiotou; Fiorella Gastaldon; Dinna N Cruz; Massimo de Cal; Maurizio Clementi; Claudio Ronco
Journal:  Int J Nephrol       Date:  2010-12-21

4.  Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment.

Authors:  Christian R Halvorson; Matthew S Bremmer; Stephen C Jacobs
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-06-24

5.  Examining the Role of Polymorphisms in Exon 25 of the PKD1 Gene in the Pathogenesis of Autosomal Dominant Polycystic Kidney Disease in ranian Patients.

Authors:  Morteza Bagheri; Khadijeh Makhdoomi; Ali Taghizadeh Afshari; Ahmad Ali Nikibakhsh; Isa Abdi Rad
Journal:  Rep Biochem Mol Biol       Date:  2019-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.